Global Information
회사소개 | 문의

고콜레스테롤혈증 : 파이프라인 리뷰

Hypercholesterolemia - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 05월 상품 코드 192645
페이지 정보 영문 203 Pages
가격
US $ 2,000 ₩ 2,257,600 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,515,200 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,772,800 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


고콜레스테롤혈증 : 파이프라인 리뷰 Hypercholesterolemia - Pipeline Review, H1 2018
발행일: 2018년 05월 페이지 정보 : 영문 203 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

고콜레스테롤혈증은 혈중 콜레스테롤의 고농도가 원인으로 발생합니다. 특히 심혈관질환으로 연결될 가능성이 있습니다. 콜레스테롤은 동맥에 침착, 혈관 협착을 일으켜 혈류를 제한합니다. 소인으로 당뇨병, 신장 질환, 비만 등 다양한 질환을 들 수 있으며, 유전, 특정 약제, 좌식 생활양식, 흡연, 알코올 중독, 스트레스, 고지방식 등도 들 수 있습니다. 증상은 동맥폐색, 하지통, 흉통, 콜레스테롤 침착 등이 있습니다. 치료에는 생활양식의 변화, 식생활 변화, 금연, 투약 등이 포함됩니다.

고콜레스테롤혈증(Hypercholesterolemia) 치료제 개발 상황에 대해 조사분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

목차

서론

고콜레스테롤혈증 개요

치료제 개발

치료제 평가

치료제 개발 참여 기업

약제 개요

휴지 상태의 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

LSH 17.07.24

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H1 2018, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 9, 13, 4, 1, 17, 5 and 3 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 6 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hypercholesterolemia - Overview
  • Hypercholesterolemia - Therapeutics Development
  • Hypercholesterolemia - Therapeutics Assessment
  • Hypercholesterolemia - Companies Involved in Therapeutics Development
  • Hypercholesterolemia - Drug Profiles
  • Hypercholesterolemia - Dormant Projects
  • Hypercholesterolemia - Discontinued Products
  • Hypercholesterolemia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hypercholesterolemia, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Hypercholesterolemia - Pipeline by AFFiRiS AG, H1 2018
  • Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by AstraZeneca Plc, H1 2018
  • Hypercholesterolemia - Pipeline by BioLingus AG, H1 2018
  • Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
  • Hypercholesterolemia - Pipeline by CymaBay Therapeutics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Daewon Pharm Co Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Daewoong Co Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Dicerna Pharmaceuticals Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Dybly AG, H1 2018
  • Hypercholesterolemia - Pipeline by Esperion Therapeutics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Gemphire Therapeutics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Golden Biotechnology Corp, H1 2018
  • Hypercholesterolemia - Pipeline by Immune Response BioPharma Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Innovent Biologics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Kadmon Corp LLC, H1 2018
  • Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Leading BioSciences Inc, H1 2018
  • Hypercholesterolemia - Pipeline by LipimetiX Development Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Madrigal Pharmaceuticals Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Medlab Clinical Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Noxopharm Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Pfizer Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Portola Pharmaceuticals Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Progenra Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
  • Hypercholesterolemia - Pipeline by RegenxBio Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1 2018
  • Hypercholesterolemia - Pipeline by The Medicines Company, H1 2018
  • Hypercholesterolemia - Pipeline by Viking Therapeutics Inc, H1 2018
  • Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2018
  • Hypercholesterolemia - Dormant Projects, H1 2018
  • Hypercholesterolemia - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Hypercholesterolemia, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research